CCL19 and neoplasm: In tumour types where regional delivery in not a feasible strategy, armouring of CAR T-cells with an appropriate chemokine (e.g., CCL19) or chemokine receptor can increase efficiency of tumour delivery, an approach that has boosted both efficacy and safety in pre-clinical testing [161].